Synlogic Discontinues SYNB1020 Development For Treating Hyperammonemia

Clinical stage company Synlogic, Inc. (SYBX) announced Tuesday that it is discontinuing development of SYNB1020, an early stage clinical product candidate for the treatment of hyperammonemia.

from RTT - Biotech https://ift.tt/31NnCMH
via IFTTT